Product Information
DOXYCYCLINE MONO 100 MG CAP is a generic product labeled by Strides Pharma Inc., priced at $0.2267 per EA under NDC 64380092201. Its NADAC has been published 41 times since Dec 24, 2025.
FDA first approved this application on Dec 1, 2000. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
100 mg/1
Manufacturer
Strides Pharma Inc.NDC
64380092201
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DOXYCYCLINEApproval Type
Generic (ANDA)
FDA Application
ANDA065055FDA Approved
12/1/2000
TE Code
AB
On Market Since
8/1/2022
Pharmacological Classes
Price Statistics
The NADAC for DOXYCYCLINE MONO 100 MG CAP has been published 41 times since Dec 24, 2025, and over the history we have for it it has declined 5.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2267 per EA |
|---|---|
| All-time high | $0.2397 (Jan 14, 2026) |
| All-time low | $0.2267 (Sep 23, 2026) |
| 52-week high | $0.2397 |
| 52-week low | $0.2267 |
| Median price | $0.2329 |
| Average price | $0.2331 |
| Largest weekly change | -2.8% (Jan 21, 2026) |
| Weeks tracked | 41 |
| Tracking since | Dec 24, 2025 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 54% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Strides Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
doxycycline market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Tetracycline-class Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DOXYCYCLINE MONO 100 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for DOXYCYCLINE MONO 100 MG CAP, manufactured by Strides Pharma Inc., is $0.2267 per EA (NDC 64380092201), effective Sep 30, 2026.
How has the price of DOXYCYCLINE MONO 100 MG CAP changed over time?
Over the history we have for it, the NADAC for DOXYCYCLINE MONO 100 MG CAP has declined 5.4%. It has been tracked across 41 weekly CMS publications since Dec 24, 2025.
What are the highest and lowest recorded NADAC prices for DOXYCYCLINE MONO 100 MG CAP?
Since Dec 24, 2025, the NADAC for DOXYCYCLINE MONO 100 MG CAP has ranged from a low of $0.2267 (Sep 23, 2026) to a high of $0.2397 (Jan 14, 2026), with a median of $0.2329 per EA.
Are there cheaper alternatives to DOXYCYCLINE MONO 100 MG CAP?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DOXYCYCLINE HYCLATE 100 MG CAP, is $0.1049 per EA — about 54% below DOXYCYCLINE MONO 100 MG CAP.
Who manufactures DOXYCYCLINE MONO 100 MG CAP?
DOXYCYCLINE MONO 100 MG CAP (NDC 64380092201) is labeled by Strides Pharma Inc., and CMS classifies it as a generic product.